MannKind Corporation (MNKD)

4.3500 +0.0200 (+0.46%) At close: 04:00PM EDT

MannKind Corporation

30930 Russell Ranch Road
Suite 300
Westlake Village, CA 91362
United States
818 661 5000
https://www.mannkindcorp.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 348

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Michael E. Castagna Pharm.D.	CEO & Director	1.12M	N/A	1977
Mr. Steven B. Binder	Chief Financial Officer	772.05k	N/A	1963
Mr. Joseph Kocinsky M.B.A., M.S.	Chief Technology Officer	608.75k	N/A	1964
Dr. David B. Thomson	Exec. VP, Gen. Counsel & Sec.	772.9k	N/A	1967
Dr. Stuart A. Tross Ph.D.	Chief People & Workplace Officer	652.85k	N/A	1967
Mr. Thomas Hofmann M.D., Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Ms. Rosabel Realica Alinaya	VP of Investor Relations & Treasury	N/A	N/A	1961
Mr. John F. Bedard	Sr. VP of Worldwide Regulatory Affairs	N/A	N/A	1950
Mr. James Patrick McCauley Jr., J.D., M.B.A.	Chief Commercial Officer	N/A	N/A	1966
Mr. Alejandro Galindo M.B.A., M.S.	Exec. VP of Endocrine Bus. Unit	N/A	N/A	1972

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.

Corporate Governance

MannKind Corporation’s ISS Governance QualityScore as of July 31, 2022 is 4. The pillar scores are Audit: 9; Board: 4; Shareholder Rights: 4; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.